Findings from St. Jude Children's Research Hospital demonstrate that virtual memory T cells, a specialized group of immune ...

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

Monday, the FDA said Sarepta may resume treating ambulatory DMD patients with Elevidys. The recommendation comes just 10 days ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

New tools and delivery vehicles for CRISPR are only truly beneficial if we can simultaneously improve the affordability and access.

The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Delivering broadly neutralizing antibodies against HIV-1 to newborns via gene therapy provided them with multi-year protection from HIV/AIDS ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...